Ohio is currently home to 3308 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
NCT06181435
Recruiting
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for SC injection compared with placebo in participant... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
04/12/2024
Locations: Velocity Clinical Research, Springdale Site Number : 8401153, Cincinnati, Ohio
Conditions: Dermatitis Atopic
Register for Updates
A Chronic Weight Management Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
NCT06143956
Recruiting
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/12/2024
Locations: CTI-CRC, Cincinnati, Ohio
Conditions: Obesity, Overweight
Register for Updates
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891
Recruiting
This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD. The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically meaningful cGVHD progression (defined as progression requiring addition of new systemic treatment for cGVHD), relapse/recurrence of the underlying disease, participant starts new systemic treatment for cGVHD or experiences an unacceptable toxicity, at the request of the part... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
04/12/2024
Locations: Oncology Hematology Care Inc Site Number : 8400030, Cincinnati, Ohio
Conditions: Chronic Graft Versus Host Disease
Register for Updates
Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
NCT06096844
Recruiting
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividin... Read More
Gender:
All
Ages:
70 years and above
Trial Updated:
04/12/2024
Locations: Strecker Cancer Center-Belpre, Belpre, Ohio
Conditions: Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Register for Updates
An Evaluation of Patient Reported Outcomes and Clinical Outcomes
NCT06092970
Recruiting
This extension study is being conducted to assess the following objectives through 12 months post-cardiac surgery: Patient reported outcomes (PRO), using the EQ-5D questionnaire Clinical outcomes
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Research Site, Cleveland, Ohio
Conditions: Post-Operative Complications in Cardiac Surgery
Register for Updates
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
NCT06081894
Recruiting
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/12/2024
Locations: The Lindner Research Center at The Christ Hospital, Cincinnati, Ohio
Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Register for Updates
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
NCT06079281
Recruiting
The primary objective of this study is to assess the efficacy of ALXN1850 versus placebo on functional outcomes in adolescent and adult participants with HPP who have not previously been treated with asfotase alfa.
Gender:
All
Ages:
Between 12 years and 130 years
Trial Updated:
04/12/2024
Locations: Research Site, Columbus, Ohio
Conditions: Hypophosphatasia
Register for Updates
Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery
NCT06021457
Recruiting
The purpose of this study is to evaluate the effect of RBT-1 on reducing the risk of post-operative complications in subjects undergoing cardiac surgery on cardiopulmonary bypass (CPB). A sub-study will also be conducted to evaluate the pharmacokinetic (PK) profile of a single administration of RBT-1 by means of a popPK approach in subjects scheduled to undergo cardiac surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Research Site, Cleveland, Ohio
Conditions: Post-Operative Complications in Cardiac Surgery
Register for Updates
Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy
NCT06005610
Recruiting
Transgender women (TW) are a key population and priority for HIV treatment. More research is needed to develop evidence-based clinical guidance when it comes to choosing antiretroviral treatment (ART) regimens for TW on feminizing hormonal therapy (FHT). Concerns about ART interacting with FHT and decreasing its effectiveness can lead to decreased ART adherence and increased viral loads. The GET IT RiGHT trial aims to address concerns about drug-drug interactions (DDIs) between ART and FHT whil... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Case CRS (2501), Cleveland, Ohio
Conditions: HIV I Infection
Register for Updates
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861
Recruiting
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may... Read More
Gender:
All
Ages:
45 years and above
Trial Updated:
04/12/2024
Locations: Research Site, Canton, Ohio
Conditions: Acute Coronary Syndrome
Register for Updates
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
NCT05814627
Recruiting
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-inhibitor who are on a stable dose of methotrexate (MTX). Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for the treatment of RA. This study is doubl... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Paramount Medical Research Con /ID# 254048, Middleburg Heights, Ohio
Conditions: Rheumatoid Arthritis
Register for Updates
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)
NCT05813275
Recruiting
This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: CTI Clinical Research Center, Cincinnati, Ohio
Conditions: OSA
Register for Updates